Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics: from bench to byte.

J J Swen1, I Wilting, A L de Goede

  • 1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Clinical Pharmacology and Therapeutics
|February 7, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.

Nature medicine·2026
Same author

Symptom Burden and Patient-Reported Outcomes in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Studies.

Kidney medicine·2026
Same author

The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations.

European journal of drug metabolism and pharmacokinetics·2025
Same author

Placental slice techniques in physiology, pathophysiology, and toxicology: A systematic review with a focus on precision-cut slices.

Placenta·2025
Same author

The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?

Expert opinion on drug metabolism & toxicology·2025
Same author

A method to measure renal inner medullary perfusion using MR renography.

Magma (New York, N.Y.)·2025
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles

Pharmacogenetic testing shows limited clinical use due to insufficient evidence of improved outcomes and interpretation challenges. Guidelines are needed to integrate pharmacogenetic results into clinical practice for better drug therapy.

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Genomic Medicine

Background:

  • Pharmacogenetic testing adoption is limited, primarily in oncology and psychiatry.
  • Lack of robust scientific evidence demonstrating improved clinical outcomes hinders widespread use.
  • Complexity in interpreting pharmacogenetic test results, especially for cytochrome P450 enzyme variants, poses challenges for healthcare professionals.

Purpose of the Study:

  • To address the limited clinical utility of pharmacogenetics.
  • To highlight the need for evidence-based guidelines linking pharmacogenetic results to therapeutic recommendations.
  • To discuss barriers in integrating pharmacogenetic information into routine clinical decision-making.

Main Methods:

  • Review of existing literature on pharmacogenetics and clinical outcomes.

Related Experiment Videos

  • Analysis of challenges in interpreting pharmacogenetic test results for physicians and pharmacists.
  • Examination of the availability and accessibility of clinical guidelines for pharmacogenetic testing.

    • Main Results:

    • Scientific evidence supporting improved clinical outcomes from pharmacogenetic testing is scarce.
    • Physicians and pharmacists require specialized pharmacological knowledge to interpret test results effectively.
    • Existing guidelines, like those for antidepressant therapy involving CYP2D6, are not readily accessible in clinical workflows.

    Conclusions:

    • Widespread clinical application of pharmacogenetics is hampered by a lack of outcome data and interpretation difficulties.
    • Development and integration of accessible clinical guidelines are crucial for the effective use of pharmacogenetics.
    • Bridging the gap between pharmacogenetic research and clinical practice is essential for personalized medicine.